CHICAGO — Erdafitinib improved OS, PFS and objective response rate compared with chemotherapy among patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. Results of the phase 3 THOR trial, presented at ASCO Annual Meeting 2023, showed the FGFR inhibitor reduced the risk for death by 36% among the patient population compared with